Although its mortality rate has reduced since 1990, the fact that clinical characteristics of breast cancer patients vary from one to another based on their age, tumor grade, tumor stage, ER and PR status, and other noncancer-related factors posed a great challenge to seek biomarkers or combined markers for the improvement of diagnosis, prognosis, and prediction of breast cancer [22–25]. This evidence concerns the gene ESR1 and breast cancer.